Background
Methods
Systematic search strategy
Inclusion and exclusion criteria
Data extraction
Quality assessment
Statistical analysis
Results
Study characteristics
Study author | Year | Country | Ethnicity | Study design | Type of CAD | Total cases/controls | Age Case / Control (Mean) | Genotyping method | Quality score |
---|---|---|---|---|---|---|---|---|---|
MMP-9 (C1562T) | |||||||||
Pollanen et al. | 2001 | Finland | European | Case-control | ACS | 109 / 167 | 33–69 / 33–69 | PCR-RFLP | 6 |
Wang et al. | 2001 | Australia | Oceania | Case-control | Stable | 619 / 169 | 57.7 ± 0.5 / NR | PCR-RFLP | 7 |
Cho et al. | 2002 | Korea | Asian | Case-control | Stable | 63 / 134 | NR / NR | PCR-RFLP | 5 |
Kim et al. | 2002 | Korea | Asian | Case-control | Stable | 131 / 117 | 61.3 ± 7.9 / 59.3 ± 8.5 | PCR-RFLP | 6 |
Jones et al. | 2002 | New Zealand | European | Case-control | Stable | 414 / 203 | 71.7 ± 7.6 / 70.8 ± 8.0 | PCR-RFLP | 8 |
Tang et al. | 2005 | China | Asian | Case-control | ACS | 101 / 105 | NR / NR | PCR-RFLP | 5 |
Chen et al. | 2005 | China | Asian | Case-control | ACS | 78 / 81 | NR / NR | PCR-RFLP | 5 |
Meng et al. | 2006 | China | Asian | Case-control | Stable | 117 / 99 | NR / NR | PCR-RFLP | 5 |
Nuzzo et al. | 2006 | Italy | European | Case-control | ACS | 49 / 123 | NR / NR | PCR-RFLP | 5 |
Chen et al. | 2007 | China | Asian | Case-control | Stable | 150 / 70 | NR / NR | PCR-RFLP | 5 |
Nanni et al. | 2007 | Italy | European | Case-control | ACS | 200 / 201 | 47.8 ± 6.2 / 47.0 ± 5.5 | PCR-RFLP | 7 |
Wang et al. | 2007 | China | Asian | Case-control | ACS | 245 / 204 | NR / NR | PCR-RFLP | 8 |
Zhang et al. | 2008 | China | Asian | Case-control | ACS | 92 / 95 | NR / NR | PCR-RFLP | 5 |
Koh et al. | 2008 | Korea | Asian | Case-control | ACS | 206 / 173 | 61.1 ± 11.8 / 58.3 ± 11.8 | PCR-RFLP | 6 |
Alp et al. | 2009 | Turkey | European | Case-control | Stable | 146 / 122 | 59.30 ± 9.1 / 57.30 ± 9.7 | PCR-RFLP | 6 |
Wu et al. | 2009 | China | Asian | Case-control | ACS | 2517 / 689 | NR / 60.42 ± 9.07 | PCR-RFLP | 8 |
Gao et al. | 2010 | China | Asian | Case-control | Stable | 96 / 78 | NR / NR | PCR-RFLP | 5 |
Fallah et al. | 2010 | Iran | Asian | Case-control | Stable | 145 / 157 | 58.49 ± 9.12 / 55.35 ± 9.43 | PCR-RFLP | 6 |
Yong et al. | 2010 | China | Asian | Case-control | ACS | 128 / 106 | NR / NR | PCR-RFLP | 5 |
Ghaderian et al. | 2010 | Iran | Asian | Case-control | ACS | 400 / 200 | NR / 65.8 ± 5.9 | TaqMan | 8 |
Zhi et al. | 2010 | China | Asian | Case-control | Stable | 762 / 555 | 67.46 ± 9.61 / 69.90 ± 11.48 | PCR-RFLP | 8 |
Wang et al. | 2011 | China | Asian | Case-control | ACS | 384 / 451 | 55.6 ± 10.9 / 54.1 ± 10.3 | PCR-RFLP | 8 |
Opstad et al. | 2012 | Norway | European | Case-control | Stable | 996 / 204 | 62 / NR | TaqMan | 8 |
Han et al. | 2012 | China | Asian | Case-control | Stable | 91 / 101 | NR / NR | PCR-RFLP | 5 |
Saracini et al. | 2012 | Italy | European | Case-control | Stable | 423 / 423 | 40–94 / 41–94 | Nano gene electronic microchip technology | 8 |
Spurthi et al. | 2012 | India | Asian | Case-control | Stable | 100 / 100 | 56.73 ± 12.2 / 54.55 ± 14.38 | PCR-RFLP | 5 |
Sewelam et al. | 2013 | Egypt | African | Case-control | ACS | 40 / 40 | NR / NR | PCR-RFLP | 5 |
Wu et al. | 2013 | China | Asian | Case-control | ACS | 258 / 153 | 63.97 ± 12.32 / 63.61 ± 11.8 | PCR-RFLP | 7 |
Xu et al. | 2013 | China | Asian | Case-control | Stable | 382 / 466 | 62 ± 12 / 62 ± 10 | PCR-RFLP | 8 |
Rodriguez et al. | 2016 | Mexico | American | Case-control | ACS | 236 / 285 | 59 / 58 | PCR-RFLP | 8 |
Yin et al. | 2016 | China | Asian | Case-control | Stable | 194 / 251 | 55.60 ± 10.42 / 56.21 ± 9.83 | PCR-RFLP | 7 |
Beton et al. | 2016 | Turkey | European | Case-control | Stable | 200 / 200 | 60.2 ± 7.4 / 58.3 ± 7.7 | PCR-RFLP | 7 |
Daraei et al. | 2016 | Iran | Asian | Case-control | ACS | 117 / 120 | 62.96 ± 12.80 / 52.55 ± 9.80 | PCR-RFLP | 6 |
El-Aziz et al. | 2016 | Egypt | African | Case-control | ACS | 184 / 180 | 57.2 ± 10.9 / 58.8 ± 8.3 | PCR-RFLP | 7 |
Qin et al. | 2016 | China | Asian | case-control | Stable | 261 / 261 | 58.75 ± 9.36 / 59.21 ± 10.10 | PCR-RFLP | 7 |
Peksiene et al. | 2017 | Lithuania | European | Case-control | ACS | 518 / 645 | 61.9 ± 11.1 / 60.6 ± 11.9 | TaqMan | 8 |
Mahmoodi et al. | 2017 | Iran | Asian | case–control | Stable | 100 / 100 | 59.4 ± 23.5 / 56.7 ± 29.5 | PCR-RFLP | 5 |
Xu et al. | 2017 | China | Asian | Case-control | Stable | 264 / 186 | 59 ± 11.67 / 58 ± 10.72 | PCR-RFLP | 7 |
Makrygiannis et al. | 2018 | Greece | European | Case-control | Stable | 175 / 166 | 72.7 ± 7.6 / 71.5 ± 7.1 | PCR-RFLP | 7 |
Malkani et al. | 2019 | Iran | Asian | Case-control | Stable | 101 / 100 | 59.2 ± 10.2 / 47.3 ± 13.1 | PCR-RFLP | 5 |
MMP-9 (R279Q) | |||||||||
Nanni et al. | 2007 | Italy | European | Case-control | ACS | 200 / 201 | 47.8 ± 6.2 / 47.0 ± 5.5 | PCR-RFLP | 7 |
Wu et al. | 2009 | China | Asian | Case-control | ACS | 2506 / 687 | NR / 60.42 ± 9.07 | PCR-RFLP | 8 |
Zhi et al. | 2010 | China | Asian | Case-control | Stable | 762 / 555 | 67.46 ± 9.61 / 69.90 ± 11.48 | PCR-RFLP | 8 |
Wang et al. | 2011 | China | Asian | Case-control | ASC | 384 / 451 | 55.6 ± 10.9 / 54.1 ± 10.3 | PCR-RFLP | 8 |
Mishra et al. | 2012 | India | Asian | Cohort | Stable | 510 / 230 | NR/ 54.2 ± 8.5 | PCR-RFLP | 8 |
Opstad et al. | 2012 | Norway | European | Case-control | Stable | 994 / 204 | 62 / NR | TaqMan | 8 |
Fiotti et al. | 2017 | Italy | European | Case-control | Stable | 169 / 169 | 69–78 / 67–80 | Sequencing | 7 |
MMP-9 (P574R) | |||||||||
Zhi et al. | 2010 | China | Asian | Case-control | Stable | 762 / 555 | 67.46 ± 9.61 / 69.90 ± 11.48 | PCR-RFLP | 8 |
Mishra et al. | 2012 | India | Asian | Cohort | Stable | 510 / 230 | NR / 54.2 ± 8.5 | PCR-RFLP | 8 |
MMP-9 (R668Q) | |||||||||
Zhi et al. | 2010 | China | Asian | Case-control | Stable | 762 / 555 | 67.46 ± 9.61 / 69.90 ± 11.48 | PCR–RFLP | 8 |
Mishra et al. | 2012 | India | Asian | Cohort | Stable | 510 / 230 | NR / 54.2 ± 8.5 | PCR–RFLP | 8 |
Study author | CAD cases | Healthy control | P-HWE | MAF | ||||||||
CC | CT | TT | C | T | CC | CT | TT | C | T | |||
MMP-9 (C1562T) | ||||||||||||
Pollanen et al. | 78 | 21 | 10 | 177 | 41 | 124 | 30 | 13 | 278 | 56 | 0 | 0/168 |
Wang et al. | 479 | 128 | 12 | 1086 | 152 | 128 | 41 | 0 | 297 | 41 | 0/072 | 0/121 |
Cho et al. | 48 | 15 | 0 | 111 | 15 | 67 | 63 | 4 | 197 | 71 | 0/016 | 0/265 |
Kim et al. | 99 | 32 | 0 | 230 | 32 | 85 | 32 | 0 | 202 | 32 | 0/086 | 0/137 |
Jones et al. | 257 | 145 | 12 | 659 | 169 | 145 | 57 | 1 | 347 | 59 | 0/063 | 0/145 |
Tang et al. | 73 | 27 | 1 | 173 | 29 | 91 | 13 | 1 | 195 | 15 | 0/494 | 0/071 |
Chen et al. | 57 | 21 | 0 | 135 | 21 | 73 | 8 | 0 | 154 | 8 | 0/640 | 0/049 |
Meng et al. | 91 | 26 | 0 | 208 | 26 | 80 | 18 | 1 | 178 | 20 | 0/991 | 0/101 |
Nuzzo et al. | 7 | 39 | 3 | 53 | 45 | 86 | 36 | 1 | 208 | 38 | 0/181 | 0/154 |
Chen et al. | 97 | 48 | 5 | 242 | 58 | 61 | 6 | 3 | 128 | 12 | 0 | 0/086 |
Nanni et al. | 136 | 62 | 2 | 334 | 66 | 135 | 63 | 3 | 333 | 69 | 0/147 | 0/172 |
Wang et al. | 191 | 52 | 2 | 434 | 56 | 178 | 25 | 1 | 381 | 27 | 0/903 | 0/066 |
Zhang et al. | 67 | 22 | 3 | 156 | 28 | 83 | 12 | 0 | 178 | 12 | 0/511 | 0/063 |
Koh et al. | 151 | 52 | 3 | 354 | 58 | 142 | 31 | 0 | 315 | 31 | 0/195 | 0/090 |
Alp et al. | 99 | 42 | 5 | 240 | 52 | 90 | 29 | 3 | 209 | 35 | 0/718 | 0/143 |
Wu et al. | 1995 | 495 | 27 | 4485 | 549 | 545 | 143 | 1 | 1233 | 145 | 0 | 0/105 |
Gao et al. | 49 | 38 | 9 | 136 | 56 | 59 | 18 | 1 | 136 | 20 | 0/775 | 0/128 |
Fallah et al. | 11 | 57 | 77 | 79 | 211 | 19 | 76 | 62 | 114 | 200 | 0/558 | 0/637 |
Yong et al. | 97 | 30 | 1 | 224 | 32 | 92 | 14 | 0 | 198 | 14 | 0/466 | 0/066 |
Ghaderian et al. | 296 | 88 | 16 | 680 | 120 | 141 | 53 | 6 | 335 | 65 | 0/708 | 0/163 |
Zhi et al. | 585 | 174 | 3 | 1344 | 180 | 442 | 110 | 3 | 994 | 116 | 0/164 | 0/105 |
Wang et al. | 286 | 87 | 11 | 659 | 109 | 373 | 72 | 6 | 818 | 84 | 0/244 | 0/093 |
Opstad et al. | 756 | 225 | 15 | 1737 | 255 | 154 | 46 | 4 | 354 | 54 | 0/794 | 0/132 |
Han et al. | 65 | 25 | 1 | 155 | 27 | 75 | 25 | 1 | 175 | 27 | 0/489 | 0/134 |
Saracini et al. | 313 | 98 | 12 | 724 | 122 | 307 | 101 | 15 | 715 | 131 | 0/071 | 0/155 |
Spurthi et al. | 40 | 47 | 13 | 127 | 73 | 48 | 46 | 6 | 142 | 58 | 0/241 | 0/290 |
Sewelam et al. | 32 | 7 | 1 | 71 | 9 | 40 | 0 | 0 | 80 | 0 | 0 | 0 |
Wu et al. | 193 | 56 | 9 | 442 | 74 | 131 | 22 | 0 | 284 | 22 | 0/337 | 0/072 |
Xu et al. | 268 | 109 | 5 | 645 | 119 | 361 | 103 | 2 | 825 | 107 | 0/059 | 0/115 |
Rodriguez et al. | 210 | 26 | 0 | 446 | 26 | 271 | 14 | 0 | 556 | 14 | 0/670 | 0/025 |
Yin et al. | 98 | 73 | 23 | 269 | 119 | 157 | 84 | 10 | 398 | 104 | 0/766 | 0/207 |
Beton et al. | 158 | 38 | 4 | 354 | 46 | 154 | 43 | 3 | 351 | 49 | 0/999 | 0/123 |
Daraei et al. | 66 | 50 | 1 | 182 | 52 | 79 | 38 | 3 | 196 | 44 | 0/528 | 0/183 |
El-Aziz et al. | 125 | 52 | 7 | 302 | 66 | 141 | 36 | 3 | 318 | 42 | 0/690 | 0/117 |
Qin et al. | 134 | 100 | 27 | 368 | 154 | 171 | 85 | 5 | 427 | 95 | 0/129 | 0/182 |
Peksiene et al. | 340 | 156 | 22 | 836 | 200 | 431 | 185 | 29 | 1047 | 243 | 0/115 | 0/188 |
Mahmoodi et al. | 68 | 27 | 5 | 163 | 37 | 72 | 26 | 2 | 170 | 30 | 0/844 | 0/150 |
Xu et al. | 188 | 69 | 7 | 445 | 83 | 151 | 31 | 4 | 333 | 39 | 0/126 | 0/105 |
Makrygiannis et al. | 133 | 40 | 2 | 306 | 44 | 133 | 31 | 2 | 297 | 35 | 0/898 | 0/105 |
Malkani et al. | 79 | 3 | 19 | 161 | 41 | 100 | 0 | 0 | 200 | 0 | 0 | 0 |
Study author | CAD cases | Healthy control | P-HWE | MAF | ||||||||
AA | AG | GG | A | G | AA | AG | GG | A | G | |||
MMP-9 (R279Q) | ||||||||||||
Nanni et al. | 85 | 94 | 21 | 264 | 136 | 94 | 87 | 20 | 275 | 127 | 0/984 | 0/316 |
Wu et al. | 1177 | 1102 | 227 | 3456 | 1556 | 297 | 312 | 78 | 906 | 468 | 0/772 | 0/341 |
Zhi et al. | 398 | 296 | 68 | 1092 | 432 | 267 | 226 | 62 | 760 | 350 | 0/179 | 0/315 |
Wang et al. | 185 | 150 | 49 | 520 | 248 | 239 | 167 | 45 | 645 | 257 | 0/052 | 0/285 |
Mishra et al. | 114 | 253 | 143 | 481 | 539 | 53 | 103 | 74 | 209 | 251 | 0/142 | 0/546 |
Opstad et al. | 405 | 472 | 117 | 1282 | 706 | 79 | 98 | 27 | 256 | 152 | 0/693 | 0/373 |
Fiotti et al. | 75 | 69 | 25 | 219 | 119 | 57 | 88 | 24 | 202 | 136 | 0/282 | 0/402 |
Study author | CAD cases | Healthy control | P-HWE | MAF | ||||||||
PP | PR | RR | P | R | PP | PR | RR | P | R | |||
MMP-9 (P574R) | ||||||||||||
Zhi et al. | 406 | 296 | 60 | 1108 | 416 | 279 | 231 | 45 | 789 | 321 | 0/770 | 0/155 |
Mishra et al. | 346 | 150 | 14 | 842 | 178 | 169 | 57 | 4 | 395 | 65 | 0/747 | 0/276 |
Study author | CAD cases | Healthy control | P-HWE | MAF | ||||||||
RR | RQ | QQ | R | Q | RR | RQ | QQ | R | Q | |||
MMP-9 (R668Q) | ||||||||||||
Zhi et al. | 564 | 179 | 19 | 1307 | 217 | 398 | 141 | 16 | 937 | 173 | 0/416 | 0/289 |
Mishra et al. | 191 | 286 | 33 | 668 | 352 | 113 | 107 | 10 | 333 | 127 | 0/012 | 0/141 |
Meta-analysis of MMP-9 (C1562T) and risk of CAD
Subgroup | Sample size | Test of association | Test of heterogeneity | Test of publication bias (Begg’s test) | Test of publication bias (Egger’s test) | |||||
---|---|---|---|---|---|---|---|---|---|---|
Genetic model | Case/Control | OR | 95% CI (p-value) | I2 (%) | P | Z | P | T | P | |
MMP-9 (C1562T) | ||||||||||
Overall | Dominant model | 11,792 / 8280 | 1.41 | 1.23–161 (≤0.001) | 68.8 | ≤0.001 | 1.48 | 0.13 | 1.62 | 0.11 |
Recessive model | 11,792 / 8280 | 1.59 | 1.29–1.96 (≤0.001) | 18.3 | 0.19 | 1.34 | 0.17 | 1.49 | 0.14 | |
Allelic model | 11,792 / 8280 | 1.38 | 1.23–1.55(≤0.001) | 68.7 | ≤0.001 | 1.39 | 0.16 | 1.54 | 0.13 | |
TT vs. CC | 11,792 / 8280 | 1.70 | 1.35–2.13 (≤0.001) | 34 | 0.42 | 1.56 | 0.11 | 2.05 | 0.04 | |
CT vs. CC | 11,792 / 8280 | 1.35 | 1.18–1.54 (≤0.001) | 65.4 | ≤0.001 | 1.48 | 0.13 | 1.62 | 0.11 | |
Subgroup | ||||||||||
Asian | Dominant model | 7483 / 5152 | 1.47 | 1.25–1.74 (≤0.001) | 64.5 | ≤0.001 | −0.72 | 0.47 | −0.14 | 0.88 |
Recessive model | 7483 / 5152 | 2.06 | 1.57–2.71 (≤0.001) | 0 | 0.45 | 1.94 | 0.05 | 1.39 | 0.18 | |
Allelic model | 7483 / 5152 | 1.45 | 1.26–1.67 (≤0.001) | 64.3 | ≤0.001 | 0.99 | 0.32 | 1.64 | 0.15 | |
TT vs. CC | 7483 / 5152 | 2.42 | 1.77–3.32 (≤0.001) | 0 | 0.45 | 0 | 1 | −0.18 | 0.86 | |
CT vs. CC | 7483 / 5152 | 1.39 | 1.19–1.64(≤0.001) | 60.8 | ≤0.001 | −0.25 | 0.80 | 0.15 | 0.88 | |
European | Dominant model | 3230 / 2331 | 1.26 | 0.97–1.66 (0.08) | 76.3 | ≤0.001 | 0.78 | 0.45 | 0.84 | 0.43 |
Recessive model | 3230 / 2331 | 1.05 | 0.75–1.47 (0.77) | 0 | 0.59 | 1.04 | 0.29 | 0.62 | 0.55 | |
Allelic model | 3230 / 2331 | 1.22 | 0.97–1.53(0.08) | 75.5 | ≤0.001 | −1.73 | 0.08 | −0.69 | 0.51 | |
TT vs. CC | 3230 / 2331 | 1.10 | 0.78–1.54 (0.59) | 32.1 | 0.15 | −0.21 | 0.83 | 0.2 | 0.82 | |
CT vs. CC | 3230 / 2331 | 1.25 | 0.96–1.64 (0.09) | 74.1 | ≤0.001 | −0.25 | 0.80 | −0.68 | 0.52 | |
ACS | Dominant model | 5862 / 4018 | 1.66 | 1.32–2.10 (≤0.001) | 76.1 | ≤0.001 | −0.25 | 0.80 | 0.89 | 0.39 |
Recessive model | 5862 / 4018 | 1.32 | 0.93–1.86 (0.12) | 2.8 | 0.416 | −0.25 | 0.80 | −0.63 | 0.54 | |
Allelic model | 5862 / 4018 | 1.57 | 1.29–1.92 (≤0.001) | 74.5 | ≤0.001 | −0.35 | 0.72 | −0.75 | 0.46 | |
TT vs. CC | 5862 / 4018 | 1.40 | 0.99–1.98 (0.06) | 35.1 | 0.11 | 0.05 | 0.96 | −0.57 | 0.57 | |
CT vs. CC | 5862 / 4018 | 1.62 | 1.28–2.04 (≤0.001) | 75 | ≤0.001 | −0.45 | 0.65 | −0.99 | 0.34 | |
Stable | Dominant model | 5930 / 4262 | 1.26 | 1.07–1.48 (≤0.001) | 60.9 | ≤0.001 | 0.38 | 0.70 | 0.24 | 0.81 |
Recessive model | 5930 / 4262 | 1.77 | 1.37–2.30 (≤0.001) | 23.6 | 0.18 | −0.12 | 0.90 | −0.42 | 0.68 | |
Allelic model | 5930 / 4262 | 1.26 | 1.09–1.46 (≤0.001) | 63.9 | ≤0.001 | 0.12 | 0.90 | −0.49 | 0.63 | |
TT vs. CC | 5930 / 4262 | 1.95 | 1.45–2.64 (≤0.001) | 31.9 | 0.10 | 1.57 | 0.11 | 14.14 | 0.04 | |
CT vs. CC | 5930 / 4262 | 1.20 | 1.03–1.39 (0.01) | 52.2 | ≤0.001 | 0.52 | 0.60 | 0.38 | 0.76 | |
MMP-9 (R279Q) | ||||||||||
Overall | Dominant model | 5525 / 2497 | 0.92 | 0.83–1.02 (0.12) | 38.7 | 0.13 | 0.05 | 0.96 | −0.23 | 0.83 |
Recessive model | 5525 / 2497 | 0.88 | 0.76–1.02 (0.08) | 0 | 0.48 | −0.18 | 0.85 | −0.21 | 0. 83 | |
Allelic model | 5525 / 2497 | 0.93 | 0.86–1(0.05) | 38.1 | 0.13 | 0.05 | 0.96 | −0.06 | 0.95 | |
GG vs. AA | 5525 / 2497 | 0.86 | 0.73–1.01(0.07) | 17.9 | 0.29 | 0.45 | 0.65 | 0.33 | 0.74 | |
AG vs. AA | 5525 / 2497 | 0.94 | 0.85–1.05 (0.26) | 29.7 | 0.20 | 0.19 | 0.85 | −0.19 | 0.85 | |
Subgroup | ||||||||||
Asian | Dominant model | 4162/ 1923 | 0.93 | 0.83–1.04 (0.19) | 45.4 | 0.13 | −0.98 | 0.32 | −1.70 | 0.18 |
Recessive model | 4162/ 1923 | 0.86 | 0.72–1.01 (0.06) | 36 | 0.19 | 0.56 | 0.57 | 0.37 | 0.73 | |
Allelic model | 4162/ 1923 | 0.92 | 0.85–1 (0.06) | 59.6 | 0.06 | 0.09 | 0.92 | −0.03 | 0.97 | |
GG vs. AA | 4162/ 1923 | 0.85 | 0.71–1.02 (0.08) | 53.7 | 0.09 | 1.16 | 0.24 | 0.92 | 0.38 | |
AG vs. AA | 4162/ 1923 | 0.95 | 0.84–1.07 (0.41) | 15.3 | 0.31 | 1.34 | 0.18 | 1.58 | 0.15 | |
European | Dominant model | 1363 / 574 | 0.91 | 0.74–1.13 (0.38) | 53.2 | 0.11 | 0.27 | 0.78 | 0.46 | 0.65 |
Recessive model | 1363 / 574 | 0.96 | 0.70–1.32 (0.80) | 0 | 0.84 | 0.55 | 0.58 | 0.74 | 0.47 | |
Allelic model | 1363 / 574 | 0.94 | 0.81–1.10 (0.45) | 10.1 | 0.32 | 0.27 | 0.78 | 0.10 | 0.92 | |
GG vs. AA | 1363 / 574 | 0.90 | 0.64–1.26 (0.53) | 0 | 0.68 | 0 | 1 | 0.38 | 0.71 | |
AG vs. AA | 1363 / 574 | 0.91 | 0.73–1.14 (0.39) | 58.9 | 0.08 | 0.52 | 0.60 | −0.47 | 0.72 | |
MMP-9 (P574R) | ||||||||||
Overall | Dominant model | 1272 / 785 | 1.05 | 0.72–1.53 (0.81) | 0.69 | 0.07 | * | * | * | * |
Recessive model | 1272 / 785 | 1.01 | 0.69–1.49 (0.95) | 0 | 0.47 | * | * | * | * | |
Allelic model | 1272 / 785 | 0.93 | 0.79–1.10 (0.41) | 0 | 0.41 | * | * | * | * | |
RR vs. PP | 1272 / 785 | 0.97 | 0.55–1.44 (0.87) | 0 | 0.38 | * | * | * | * | |
PR vs. PP | 1272 / 785 | 1.03 | 0.72–1.48 (0.87) | 63.7 | 0.09 | * | * | * | * | |
MMP-9 (R668Q) | ||||||||||
Overall | Dominant model | 1272 / 785 | 1.19 | 0.66–2.13 (0.56) | 88.3 | ≤0.001 | * | * | * | * |
Recessive model | 1272 / 785 | 1.12 | 0.68–1.84 (0.64) | 21.2 | 0.26 | * | * | * | * | |
Allelic model | 1272 / 785 | 1.11 | 0.73–1.69 (0.62) | 85.1 | 0.01 | * | * | * | * | |
QQ vs. RR | 1272 / 785 | 1.26 | 0.55–2.89 (0.58) | 63.1 | 0.01 | * | * | * | * | |
RQ vs. RR | 1272 / 785 | 1.18 | 0.68–2.06 (0.43) | 86.4 | ≤0.001 | * | * | * | * |